RecruitingNot ApplicableNCT04251377

Single-stage Surgery With Antibiotic-loaded Hydrogel Coated Implants Versus Two Stage Surgery for Secondary Prevention of Complex Chronic Periprosthetic Hip Joint Infection

Single-stage Surgery With Antibiotic-loaded Hydrogel Coated Implants Versus Two Stage Surgery for Secondary Prevention of Complex Chronic Periprosthetic Hip Joint Infection SINBIOSE-H.


Sponsor

Centre Hospitalier Universitaire de Saint Etienne

Enrollment

440 participants

Start Date

Sep 30, 2021

Study Type

INTERVENTIONAL

Conditions

Summary

Each year, around 1500 infected Total Hip Arthroplasties (THA) need non-conservative surgery, remaining an issue for patients and healthcare units. The recommended treatment, relying on cohort reviews and international consensus follows a two-stage protocol. This protocol implies a first surgery to remove all infected implants and at least 6 weeks of antibiotic treatment without implant, then usually an antibiotic-free period and only then a second surgery to put back new implants and start the rehabilitation protocol, with usually more than a week of a second hospital stay. Between both surgeries, full-weight bearing is prohibited and joint stiffness and/or pain are rather usual complications. Failure rate is estimated at 10% in this two-stage strategy. The single-stage procedure (i.e. implanting back a new prosthesis during the same surgery after implant removal, synovectomy and lavage) is thought to be less susceptible to late functional complications (i.e. pain, stiffness and muscle deficiency) with a shorter, single hospital stay. Although, with single-stage surgery, infection control could be less efficient because most pathogens produce during the first hours of infection an antibiotic-resistant layer called biofilm, allowing them to colonize and adhere to foreign objects like implants. This single-surgery protocol thus highly relies on antibiotics and has a list of contra-indications (based on experts' consensus): the presence of damaged soft tissues or a sinus tract, unknown pathogens, difficult to treat micro-organisms, severe immunosuppression and for many surgeons, each time a bone graft is necessary. Most of these contra-indications are directly related to the biofilm. As no randomized control trial has ever compared single-stage versus two-stage surgery, the level of evidence for recommending one procedure over the other is low. We conducted a survey that showed that most of the French reference centers have already switched to single stage surgery for single-stage non contra-indicated cases. An antibiotic-loaded hydrogel coating (Defensive Antiadhesive Coating®, Novagenit SRL), has been proven to mechanically prevent the biofilm formation, while allowing a prolonged intraarticular antibiotic release, in a randomized controlled trial in primary prevention of infection in THA. The addition of this biofilm inhibitor to a single-stage surgery might stand as a promising strategy for secondary prevention of peri-prosthetic hip joint infection. Moreover, using this device to prevent biofilm formation could expand one stage surgery to patients that are "normally" contra-indicated to one stage surgery.


Eligibility

Min Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This French randomized controlled trial compares two surgical strategies for treating chronic periprosthetic hip joint infection (PJI) — a serious infection around a hip replacement implant. The current gold standard is a two-stage surgery: first remove the infected implant, treat with antibiotics, then do a second operation to put in a new joint. This trial tests whether a single-stage revision surgery using an antibiotic-coated implant can achieve similarly good infection control with less burden on the patient. The antibiotic-loaded hydrogel coating on the implant slowly releases antibiotics locally, targeting bacteria at the surgical site. Participants must have a confirmed chronic hip PJI meeting established diagnostic criteria and be 18 or older. You may be eligible if... - You have a chronic periprosthetic hip joint infection confirmed by established diagnostic criteria (positive cultures, sinus tract, or multiple minor criteria) - You are 18 or older - You are covered by French social security and can give signed informed consent You may NOT be eligible if... - You have a known allergy to the hydrogel coating components (hyaluronic acid or poly-lactic acid) - You are pregnant (or have a positive pregnancy test) - Your life expectancy is less than 3 months - You require a cemented implant for your surgery - You cannot provide informed consent Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DEVICEDefensive Antiadhesive Coating DAC®, Novagenit SRL

DAC gel, mixed with topical antibiotics is applied on the surface of the implants before implantation, in a sterile environment in the operating room. The topical antibiotics will be added to the reconstituted DAC® gel preparation, at the discretion of the physician, on the basis of pre-operative culture.


Locations(14)

CHU Amiens

Amiens, France

CHU Bordeaux

Bordeaux, France

CHU Caen

Caen, France

CHU Clermont-Ferrand

Clermont-Ferrand, France

CHU Dijon

Dijon, France

CHU Lille

Lille, France

HCL - Hôpital de la Croix Rousse

Lyon, France

HCL - Hôpital Edouard Herriot

Lyon, France

CHU Marseille

Marseille, France

CHU Nancy

Nancy, France

CHU Nantes

Nantes, France

CHU Nice

Nice, France

Chu Saint-Etienne

Saint-Etienne, France

CHU Toulouse

Toulouse, France

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT04251377


Related Trials